Inhibition of the KRAS downstream effectors, MEK1/2, in CRC cell lines carrying activating KRAS mutations (HCT116, DLD1, LoVo, SW480) has also been shown to inhibit expression of Snail1 and Snail2 [75], indicating that expression of these key EMT factors is likely dependent on KRAS signaling in these cell lines. Here, KRAS is linked to colorectal carcinoma.